← Back to Clinical Trials
Recruiting NCT06816056

NCT06816056 Manual Therapy in Hemophilic Arthropathy of the Ankle

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06816056
Status Recruiting
Phase
Sponsor Investigación en Hemofilia y Fisioterapia
Condition Hemophilia A
Study Type INTERVENTIONAL
Enrollment 13 participants
Start Date 2025-02-05
Primary Completion 2025-07-21

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Manual TherapyPlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 13 participants in total. It began in 2025-02-05 with a primary completion date of 2025-07-21.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Introduction: Haemophilic ankle arthropathy manifests as functional (deficit in muscle strength, mobility and proprioception), intra-articular degenerative alterations and chronic pain. Manual therapy techniques are characterised by treating the soft tissues with the aim of modifying their density, relieving pain, reducing tissue sensitivity and improving the ranges of mobility. The objective is to evaluate the safety and effectiveness of a manual therapy protocol in patients with haemophilic ankle arthropathy. Methods: Randomised crossover clinical trial. 13 patients with haemophilic ankle arthropathy from different regions of Spain will be recruited and randomised into two study groups (experimental and control). Each session of the experimental group will last 50 minutes, with 1 physiotherapy session per week for a period of 3 weeks. Patients will be evaluated at the beginning of the study, after the intervention and after a follow-up period of 4 weeks. The treatment programme includes 10 techniques that must be administered bilaterally. The study variables are the frequency of ankle haemarthrosis, range of movement, pressure pain threshold, pain intensity, joint status, biomechanical analysis of gait and balance, functionality and kinesiophobia. Expected results: To evaluate the safety of manual therapy in patients with haemophilia. To observe changes in pain, mobility, joint condition, stability and functionality of the ankle, and kinesiophobia.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with haemophilia A and B * With severe haemophilia phenotype (\<1% FVIII/FIX) * Over 18 years of age * With a medical diagnosis of ankle arthropathy and with clinical assessment using the Hemophilia Joint Health Score * On prophylactic or on-demand treatment with coagulation factor VIII/FIX concentrates Exclusion Criteria: * Patients with neurological or cognitive disorders that prevent them from understanding the questionnaires and physical tests * Failure to sign the informed consent document

Contact & Investigator

Central Contact

Rubén Cuesta-Barriuso, PhD

✉ cuestaruben@uniovi.es

📞 607547274

Principal Investigator

Rubén Cuesta-Barriuso, PhD

PRINCIPAL INVESTIGATOR

Universidad de Oviedo

Frequently Asked Questions

Who can join the NCT06816056 clinical trial?

This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Hemophilia A. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06816056 currently recruiting?

Yes, NCT06816056 is actively recruiting participants. Contact the research team at cuestaruben@uniovi.es for enrollment information.

Where is the NCT06816056 trial being conducted?

This trial is being conducted at Murcia, Spain.

Who is sponsoring the NCT06816056 clinical trial?

NCT06816056 is sponsored by Investigación en Hemofilia y Fisioterapia. The principal investigator is Rubén Cuesta-Barriuso, PhD at Universidad de Oviedo. The trial plans to enroll 13 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology